ArticleInternational journal of cancer2018
Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 66 citations in OpenAlex.
- Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms.RSC chemical biology · 2026Review
- Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy.Npj imaging · 2026Article
- Article
- Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death.Molecular therapy. Oncology · 2025Article
- Targeting Glioblastoma Stem Cells: A40s Aptamer-NIR-Dye Conjugate for Glioblastoma Visualization and Treatment.Biomolecules · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeted Elimination of Influenza Virus and Infected Cells with Near-Infrared Antiviral Photoimmunotherapy (NIR-AVPIT).Pharmaceutics · 2025Article
- Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review.Cancer management and research · 2025Review
- Immunomodulatory R848-Loaded Anti-PD-L1-Conjugated Reduced Graphene Oxide Quantum Dots for Photothermal Immunotherapy of Glioblastoma.Pharmaceutics · 2024Article
- Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer.International journal of molecular sciences · 2024Article
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Near-infrared photoimmunotherapy in cancer treatment: a bibliometric and visual analysis.Frontiers in pharmacology · 2024Article
- Article
- Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors.Cancer immunology, immunotherapy : CII · 2023Article
- Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer.International journal of cancer · 2023Article
- Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.International journal of molecular sciences · 2023Review
- Article
- Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective.Biomedicines · 2022Review
- Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.Pharmaceutics · 2022Review
- Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.BMC medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (Z
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.